Montelukast Teva

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as a tablet for oral use. It helps control asthma symptoms and alleviates allergic rhinitis in adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to manage chronic respiratory and allergic conditions. - Asthma: reduces bronchoconstriction and airway inflammation, improving breathing control. - Allergic rhinitis: eases nasal congestion, sneezing and itchy eyes caused by allergens. - Exercise‑induced bronchoconstriction: helps prevent airway narrowing during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional irritation of the throat. - Nausea: feeling of sickness or urge to vomit. - Dizziness: transient light‑headedness. - Fatigue: unusual tiredness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Angioedema: rapid swelling of face, lips or throat. - Hepatic injury: elevated liver enzymes or hepatitis. - Neuropsychiatric events: depression, anxiety, or suicidal thoughts. - Anaphylaxis: life‑threatening allergic reaction. - Severe rash: widespread skin eruptions.

Before using Montelukast, consider the following safety measures. - Neuropsychiatric monitoring: watch for mood changes, depression or suicidal ideation. - Liver function: use cautiously in patients with hepatic impairment. - Hypersensitivity: avoid if known allergy to montelukast or any excipients. - Asthma control assessment: ensure baseline control before initiation. - Drug interaction review: evaluate concomitant medicines for potential interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Rifampin: strong CYP3A4 inducer that can lower montelukast levels. - Phenobarbital: enzyme inducer reducing therapeutic effect. - Ketoconazole: potent CYP3A4 inhibitor that may increase montelukast exposure.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of gastrointestinal irritation. - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Oral contraceptives: possible change in hormone levels; observe for efficacy.